Lung Cancer

Retevmo improved event-free survival in stage 2 to 3A RET fusion-positive non-small cell lung cancer after curative therapy, per phase 3 data.

Heather Quintana Suchan, a nonsmoker with stage 4 lung cancer, credits genomic testing and Rybrevant and urges others not to ignore mild symptoms.

A nurse practitioner explains how FDA approval of subcutaneous Rybrevant may reduce treatment burden and improve care for patients with EGFR-mutated lung cancer.

Showing up taking notes and learning the disease can help families feel empowered as new treatments expand hope and quality of life.

The U.S. FDA has granted Regenerative Medicine Advanced Therapy designation to KB707 for the treatment of advanced/metastatic non-small cell lung cancer.

Dr. Joshua Sabari tells CURE that surgery, radiation and systemic therapy can affect the lungs, and he urges exercise and reporting new symptoms early.

Lung carcinoid tumors are rare and often slow growing. Treatment depends on stage and tumor type, with surgery common early and systemic options for advanced disease.

The FDA accepted an application for ivonescimab with chemotherapy for patients with lung cancer driven by EGFR changes after prior targeted treatment.

Small cell lung cancer grows quickly. Learn how it’s diagnosed, staged and treated, and what patients can expect from therapies and side effects.

Patients should understand their cancer, treatment goals and options and record questions to support informed, productive discussions with care teams.

An expert explains how a DLL3 blood test may help guide Imdelltra use and set expectations for patients with small cell lung cancer.

Learn about large cell lung cancer, from diagnosis to stage-specific treatments, side effects and care options to guide patients through their journey.

A U.S. phase 1 trial of Alveltamig opened at UK Markey, where the first patient with small cell lung cancer was treated in late October.

The American Cancer Society’s 2026 Cancer Statistics report shows the five-year survival rate for all cancers has reached a record high of 70%.

I live with cancer, but I don’t let it define me. I choose to define my story by courage, trust, and hope.

After Donna Rigby visited the emergency department at Hackensack Meridian Jersey Shore University Medical Center, tests showed stage 2 lung cancer.

Lung squamous cell carcinoma starts in airway lining cells; treatment depends on stage, from surgery to systemic therapies, with side effects to monitor.

FDA granted breakthrough therapy designation to zoldonrasib for previously treated KRAS G12D-mutated non-small cell lung cancer.

From new imaging and targeted therapies to patient journeys, 2025 highlighted key advances and personal stories in lung cancer care and awareness.

Early trial data suggest Olvi-Vec may shrink or control cancer after platinum therapy, with safety signals in small cell and non-small cell lung cancer.

The EVEREST-2 study has reported the first complete response to CAR-T cell therapy in a patient with non-small cell lung cancer.

CURE spoke with an expert about smoking-related stigmas often faced by patients with lung cancer.

Ceralasertib plus Imfinzi failed to improve overall survival versus docetaxel in a phase 3 study of previously treated non-small cell lung cancer.

CURE spoke with a clinical psychologist about the stigmas often faced by patients with lung cancer.

The FDA has granted approval to Rybrevant Faspro, the first and only subcutaneous therapy for EGFR-mutated non-small cell lung cancer.